Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy

We improve the potency of antibody-drug conjugates (ADCs) containing the HER2-specific antibody pertuzumab by reducing their affinity for HER2 by >250-fold at acidic endosomal pH relative to near neutral pH. These engineered pertuzumab variants show increased lysosomal delivery and cytotoxicity t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Jeffrey C., Sun, Wei, Khare, Priyanka, Karimi, Mostafa, Wang, Xiaoli, Shen, Yang, Ober, Raimund J., Ward, E. Sally
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668989/
https://www.ncbi.nlm.nih.gov/pubmed/30936563
http://dx.doi.org/10.1038/s41587-019-0073-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668989/
https://www.ncbi.nlm.nih.gov/pubmed/30936563
http://dx.doi.org/10.1038/s41587-019-0073-7

Ejemplares similares